Skip to main content



Dr. Hardik Chhatrala is board-certified in hematology and oncology and practices at our Southside and Southpoint locations. Dr. Chhatrala received his Bachelor of Medicine and Bachelor of Surgery from Pramukhswami Medical College in India. After moving to America, he received his Master of Public Health from Drexel University and his Doctor of Medicine from Western Michigan University. He then completed his hematology/oncology fellowship at the University of Florida Health in Jacksonville.

Dr. Chhatrala has a patient-first philosophy, which helps him develop strong bonds, openness, and trusts with patients and their families. “I love when I’m able to use my training to demystify and explain the process of treating cancer and blood disorders,” says Dr. Chhatrala. He continues, saying:

“In doing so, I’m able to help turn their confusion and fear into courage and resilience as they battle cancer. It’s always gratifying to see patients go into remission, or even be cured, after treatment. I hope that my patients always remember that I am their ally in this fight; I’m someone who is frank and will explore all available treatment options and help making choices that work best for them as individuals.”

About CSNF, Dr. Chhatrala says: “I’m proud to work for a company with such a diverse group of physicians and staff that have a singular goal of providing advanced, compassionate, and patient-focused care.”

When not in the office, Dr. Chhatrala enjoys spending time with his wife and 3-year old son, relaxing at the beach, and playing racquetball and cricket.

Curriculum Vitae


Internal Medicine


American Society of Clinical Oncology
American Society of Hematology


University of Florida Health, Jacksonville


Western Michigan University
Doctor of Medicine
Drexel University
Master of Public Health
Pramukhswami Medical College
Bachelor of Medicine and Bachelor of Surgery


Journal of Clinical Onc.
Demographic variables and risk factors associated with 30 Day Readmission Following Bone Marrow Transplant: Analysis of Nationwide Inpatient Sample Data
Journal of Clinical Onc.
Demographic variables and risk factors associated with 30 Day Readmission Following Colon Cancer: Analysis of Nationwide Inpatient Sample Data 2009-2013
Journal of Clinical Onc.
Survival difference among patients with hepatocellular carcinoma (HCC) based on stage of disease: The pre- and post-sorafenib era.
Journal of Clinical Onc.
Combined hepatocellular carcinoma and cholangiocarcinoma: Debate for the ideal surgical option
American J. of Gastroenterology
Hepatorenal Syndrome: 2000-2014 Inpatient Hospitalization and Mortality Trends
Journal of Clinical Onc.
Prognostic implication of GATA3 gene mutation on survival in invasive ductal carcinoma of the breast.
J. of Investigative Med.
A Rare Case of Triple Positive Metachronous Breast Cancer
Sage Journals
Triple-Negative Lobular Breast Cancer Causing Hydronephrosis
BMJ Case Rep.
Proptosis and ovarian masses: extramedullary manifestations of acute myeloid leukaemia